Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) EVP Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 1st. The stock was sold at an average price of $581.53, for a total transaction of $639,683.00. Following the completion of the transaction, the executive vice president now owns 19,644 shares in the company, valued at approximately $11,423,575.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Marion Mccourt also recently made the following trade(s):
- On Friday, July 1st, Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $587.76, for a total transaction of $646,536.00.
Regeneron Pharmaceuticals Trading Up 5.9 %
NASDAQ:REGN opened at $608.77 on Thursday. Regeneron Pharmaceuticals, Inc. has a one year low of $538.01 and a one year high of $747.42. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.76 and a quick ratio of 4.09. The company’s 50-day simple moving average is $601.43 and its 200 day simple moving average is $635.97. The firm has a market capitalization of $66.08 billion, a P/E ratio of 8.62, a PEG ratio of 1.76 and a beta of 0.29.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of REGN. Capital International Investors raised its holdings in shares of Regeneron Pharmaceuticals by 533.0% during the first quarter. Capital International Investors now owns 1,683,899 shares of the biopharmaceutical company’s stock valued at $1,176,069,000 after purchasing an additional 1,417,899 shares during the last quarter. Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $609,222,000. Capital World Investors raised its holdings in shares of Regeneron Pharmaceuticals by 11.8% during the first quarter. Capital World Investors now owns 5,949,834 shares of the biopharmaceutical company’s stock valued at $4,155,451,000 after purchasing an additional 626,199 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Regeneron Pharmaceuticals by 11.9% during the fourth quarter. JPMorgan Chase & Co. now owns 4,591,529 shares of the biopharmaceutical company’s stock valued at $2,899,642,000 after purchasing an additional 489,084 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Regeneron Pharmaceuticals by 6.8% during the first quarter. State Street Corp now owns 5,125,467 shares of the biopharmaceutical company’s stock valued at $3,579,729,000 after purchasing an additional 325,645 shares during the last quarter. 83.83% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on REGN shares. Cowen raised their price target on shares of Regeneron Pharmaceuticals from $635.00 to $645.00 in a report on Wednesday, July 20th. Cowen raised their price target on shares of Regeneron Pharmaceuticals from $635.00 to $645.00 and gave the stock a “market perform” rating in a report on Wednesday, July 20th. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $610.00 to $619.00 and gave the stock an “equal weight” rating in a report on Friday, July 15th. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $750.00 to $735.00 and set an “overweight” rating on the stock in a report on Friday, June 3rd. Finally, Evercore ISI set a $635.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, June 20th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $697.15.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Regeneron Pharmaceuticals (REGN)
- There Are Different Types of Stock To Invest In
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- Is Starbucks Shooting For The Moon?
- Two High-Yield Deep-Values You Shouldn’t Ignore
- PayPal Continues To Struggle As Competition Increases
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.